Skip to Content

Prophylaxis and Management of Skin Toxicities with Amivantamab (Rybrevant) and Lazertinib (Lazcluze) Treatment: The COCOON Protocol

Download PQI pdf 0.37MB

Last Updated: August 7, 2025

By: Sharon Zhong, PharmD, BCOP

About this PQI

This document outlines an evidence-based approach to the prevention of dermatologic toxicities, informed by the Phase 2 COCOON trial, along with management strategies for patients receiving amivantamab and lazertinib for EGFR-mutant advanced non–small cell lung cancer (NSCLC).

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI